Celltrion Promotes Products at World's Largest IBD Conference

Research Results of Remsima SC to Be Presented at ECCO

Celltrion Remsima SC. Photo by Celltrion

Celltrion will participate in the '2025 European Crohn’s and Colitis Organization (ECCO)' held in Berlin, Germany, from the 19th to the 22nd of this month (local time) for four days, promoting the competitiveness of autoimmune disease treatments such as Remsima SC (generic name infliximab; U.S. product name Zimpentra) to leading experts in the field of Inflammatory Bowel Disease (IBD).

ECCO is one of the core global IBD conferences. More than 8,000 healthcare professionals from around the world, including Europe, North America, and Asia, attend annually to discuss the latest clinical research and trends in drug development. Marking its 20th anniversary, this year’s event is themed 'Sustainability in IBD and Beyond.' Celltrion is the only Korean company participating as an official sponsor and plans to conduct various programs at a dedicated booth, carrying out marketing activities befitting a leading company in the K-bio industry.

First, Celltrion will deliver an oral presentation on 'Endoscopic and histological study results of moderate to severe ulcerative colitis (UC) patients treated with Remsima SC.' Additionally, three posters will be presented: 'Clinical recovery time following dose escalation of Remsima SC in patients with loss of response,' 'Efficacy of Remsima SC maintenance therapy according to intestinal disease location in Crohn’s Disease (CD) patients,' and 'Impact of immunogenicity in two-year clinical results of CD patients.'

Moreover, Celltrion will hold seminars at its booth for conference attendees, introducing 'Long-term treatment effects of Remsima SC experienced by IBD healthcare professionals in real clinical settings' and 'Real-world data research results of Remsima SC prescriptions by patient cases such as obesity.' On the 21st, a symposium titled 'Early Treatment of IBD Patients: Realizing the Potential of Timely Advanced Therapy' will be held.

Based on newly released research data at ECCO, the global prescription expansion of Remsima SC is expected to accelerate further. Remsima SC is a subcutaneous (SC) formulation of infliximab, which has been used worldwide for over 20 years with proven efficacy and safety. It continues to show rapid prescription growth by emphasizing the advantages of dosing convenience and treatment efficacy. Last year, it was also launched in the U.S. market under the product name 'Zimpentra,' signaling another leap forward in expanding its global market share.

According to IQVIA, a pharmaceutical market research firm, Remsima SC achieved approximately 25% market share in the five major European countries (Germany, Spain, the United Kingdom, Italy, France; EU5) as of the third quarter of last year. Notably, it recorded overwhelming prescription results with market shares of 43% and 30% in Germany and France, respectively. When combined with the Remsima intravenous (IV) formulation, the market share in the EU5 countries reaches 79%.

Interest is also rising locally regarding Stekima (generic name ustekinumab), which was launched in Europe at the end of last year. Active product promotion activities targeting healthcare professionals attending ECCO are planned. Since Stekima overlaps in prescribing physicians with the Remsima product line (IV and SC) and Uplyma (generic name adalimumab), Celltrion plans to quickly capture the market by actively utilizing the human networks established through sales of these existing products.

A Celltrion representative stated, "We expect the preference for Remsima SC to increase significantly through the newly presented research data. The product’s trustworthiness will also rise in regions where prescription expansion and product launches continue, including not only Europe, where it has already successfully established itself, but also the U.S., Asia, and Latin America. With the launch of Stekima, we will have a strong portfolio of four IBD treatments. We plan to strengthen our market influence by pursuing marketing strategies that maximize synergy among products for key stakeholders."

This content was produced with the assistance of AI translation services.